Is STAAR Surgical (STAA) overvalued or fairly valued?

MarketChacha shows STAAR Surgical's valuation in context — a forward P/E of about 23.3, a price-to-book of about 3.3 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is STAAR Surgical's revenue?

STAAR Surgical reported revenue of $239.4M for FY2026, with net profit of $-80.4M, per official filings.

What is the share price of STAAR Surgical (STAA)?

STAAR Surgical last traded at $23.47 (-0.5% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

STAAR Surgical

STAA · NYSE · Healthcare · United States

Snapshot

TickerSTAA

ExchangeNYSE

SectorHealthcare

IndustryMedical Instruments & Supplies

CountryUnited States

Employees921

HeadquartersLake Forest, United States

Websitewww.staar.com

Filings tracked25

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Who owns it

Insiders0.9%
Institutions99.1%
Public & other0.0%

283 institutional holders

Ownership breakdown from public market data.

Top holders

Broadwood Capital, Inc.32.16%
Blackrock Inc.13.42%
Madison Avenue Partners, LP8.33%
Yunqi Capital Ltd6.50%
Point72 Asset Management, L.P.4.86%
Goldman Sachs Group Inc4.29%
Vanguard Portfolio Management LLC3.95%
State Street Corporation3.53%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 40.2 points over the period — profitability is trending down.

Net margin trend6.6% → -33.6%

Margin has compressed by about 40.2 points over the period — profitability is trending down.

Return on equity-23.4%

Latest ROE of -23.4% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $68.3M · EPS 0.09

Est. earnings growth +959.8%

Next fiscal year

Rev $361.0M · EPS 1.02

Est. earnings growth +34.3%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2026)

$239.4M

Net margin

-33.6%

ROE

-23.4%

Revenue CAGR (2y)

-13.8%

EPS (FY2026)

-1.62

Net profit (FY2026)

$-80.4M

Ask MarketChacha about STAA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2026	$239.4M	$-80.4M	-1.62	-33.6%	-23.4%
FY2024	$313.9M	$-20.2M	-0.41	-6.4%	-5.1%
FY2023	$322.4M	$21.3M	0.43	6.6%	5.5%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$93.5M	$5.2M	0.10	5.6%
2025Q3	$94.7M	$8.9M	0.18	9.4%
2025Q2	$44.3M	$-16.8M	-0.34	-37.9%
2025Q1	$42.6M	$-54.2M	-1.10	-127.3%
2024Q3	$88.6M	$10.0M	0.20	11.3%
2024Q2	$99.0M	$7.4M	0.15	7.5%
2024Q1	$77.4M	$-3.3M	-0.07	-4.3%
2023Q3	$80.3M	$4.8M	0.10	6.0%
2023Q2	$92.3M	$6.1M	0.12	6.6%
2023Q1	$73.5M	$2.7M	0.05	3.7%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC8/6/2026material
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC6/22/2026material
8-K — Executive/director change
SEC6/9/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC5/13/2026material
10-Q filing
SEC5/13/2026
8-K — Reg FD disclosure, Exhibits
SEC4/8/2026material
10-K filing
SEC3/3/2026
8-K — Results of operations, Reg FD disclosure
SEC3/3/2026material
8-K — Executive/director change
SEC2/5/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC2/2/2026material
8-K — Executive/director change
SEC1/16/2026material
8-K — Material agreement, Delisting notice, Executive/director change, Other events, Exhibits
SEC1/15/2026material
8-K — Other events, Exhibits
SEC1/6/2026material
8-K — Termination of agreement, Shareholder vote results
SEC1/6/2026material

2025

8-K — Material agreement, Exhibits
SEC12/9/2025material
8-K — Other events, Exhibits
SEC12/8/2025material
8-K — Material agreement, Other events, Exhibits
SEC11/7/2025material
8-K — Results of operations, Exhibits
SEC11/5/2025material
10-Q filing
SEC11/5/2025
8-K — Other events, Exhibits
SEC10/27/2025material
8-K — Other events, Exhibits
SEC10/23/2025material
8-K — Results of operations, Exhibits
SEC10/20/2025material
8-K — Other events
SEC10/14/2025material
8-K — Reg FD disclosure, Exhibits
SEC9/26/2025material
8-K — Results of operations, Exhibits
SEC8/6/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.